Pfizer Wins Bidding War for Obesity Drugmaker Metsera, Outmaneuvering Novo Nordisk
A decisive move by Pfizer secures a foothold in the burgeoning weight-loss market, ending a fierce competition with industry leader Novo Nordisk.
Pfizer has reached an agreement to acquire Metsera Inc., a New York-based pharmaceutical company developing novel treatments for obesity and diabetes, effectively winning a high-stakes bidding war against Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy. The acquisition signals Pfizer’s renewed commitment to the lucrative market for metabolic disease therapies, despite previously halting development of its own obesity pill earlier this year.
Metsera, while currently without any marketed products, has been focused on developing both oral and injectable treatments with the potential to address significant unmet needs in the treatment of obesity and related metabolic disorders. This includes potential therapies targeting both obesity and diabetes, two conditions with a growing global prevalence.
The deal, announced Friday, will see Pfizer acquire Metsera for up to $86.25 per share. This comprises $65.60 per share in cash, alongside a contingent value right (CVR) that could provide additional payments of up to $20.65 per share, contingent upon the achievement of certain future milestones.
According to a statement released by Metsera, the company’s board determined that Pfizer’s revised offer presented “the best transaction for shareholders, both from the perspective of value and certainty of closing.” A key factor in this decision appears to be concerns surrounding potential U.S. antitrust risks associated with Novo Nordisk’s bid.
The acquisition follows a dramatic escalation in bidding over the past week. Novo Nordisk raised its offer to as much as $10 billion for Metsera on Tuesday, exceeding its previous bid of up to $9 billion, a move that initially prompted a lawsuit from Pfizer. Pfizer responded by increasing its own offer, initially made in September for nearly $4.9 billion, to include a larger upfront cash component.
Pfizer expressed satisfaction with the finalized terms of the agreement, stating in an email that the company anticipates closing the transaction shortly after a Metsera shareholder meeting scheduled for November 13. Novo Nordisk, however, announced Saturday that it would withdraw from the bidding process, declining to further increase its offer.
Novo Nordisk’s final proposal involved a cash payment of $62.20 per Metsera share, up from a previous bid of $56.50, coupled with a CVR payment of $24, contingent on the successful completion of development and regulatory hurdles.
This acquisition represents a strategic win for Pfizer as it seeks to establish a stronger presence in the rapidly expanding market for obesity treatments. The company now possesses a pipeline of potential therapies that could compete with Novo Nordisk’s dominant position, and analysts predict further consolidation within the sector as pharmaceutical companies race to capitalize on the growing demand for effective weight-loss solutions.
